GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

GSK has announced that it will be expanding its immunology pipeline by acquiring a clinical-stage T cell-engager from ...

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year after what it called lower-than-expected demand.

GSK's vaccine sales, including RSV and Shingrix, decline amid changing US recommendations, impacting Q3 performance and ...

GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire ...

GSK inks agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline: London, UK Thursday, October 31, 2024, 10:00 Hrs [IST] GSK plc and Chimagen Bioscien ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

UK pharma major GSK is to buy CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from privately-held ...

The collaboration agreement was signed by Dr. Ramadan Al Blooshi, Advisor to the Director General and Acting Director of the ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...